BeOne Medicines (NASDAQ:ONC) Stock Price Expected to Rise, Truist Financial Analyst Says

BeOne Medicines (NASDAQ:ONC) had its target price increased by investment analysts at Truist Financial from $400.00 to $412.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s target price would indicate a potential upside of 29.29% from the stock’s previous close.

ONC has been the subject of several other reports. Citigroup upped their target price on shares of BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Royal Bank Of Canada reissued an “outperform” rating and issued a $425.00 price target (up from $417.00) on shares of BeOne Medicines in a report on Thursday. Guggenheim lifted their price objective on BeOne Medicines from $400.00 to $410.00 and gave the stock a “buy” rating in a report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $420.00 target price on shares of BeOne Medicines in a research report on Monday, November 17th. Finally, Sanford C. Bernstein raised shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target for the company in a research report on Monday, January 12th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $388.00.

BeOne Medicines Stock Down 1.1%

Shares of NASDAQ:ONC traded down $3.70 during midday trading on Friday, hitting $318.67. 142,149 shares of the company’s stock traded hands, compared to its average volume of 280,820. The firm’s fifty day moving average price is $336.79 and its two-hundred day moving average price is $330.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. BeOne Medicines has a twelve month low of $196.45 and a twelve month high of $385.22. The company has a market cap of $34.95 billion, a PE ratio of 624.84 and a beta of 0.52.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($1.02). BeOne Medicines had a return on equity of 5.52% and a net margin of 1.38%.The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. On average, equities research analysts anticipate that BeOne Medicines will post -5.82 EPS for the current fiscal year.

Insider Activity

In related news, CEO John Oyler sold 75,631 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $307.79, for a total transaction of $23,278,465.49. Following the sale, the chief executive officer owned 24,369 shares in the company, valued at $7,500,534.51. This represents a 75.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 102,656 shares of company stock valued at $31,567,496 over the last ninety days. Company insiders own 6.62% of the company’s stock.

Institutional Trading of BeOne Medicines

A number of large investors have recently modified their holdings of ONC. EFG International AG bought a new position in BeOne Medicines in the 4th quarter worth about $25,000. Anchor Investment Management LLC bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $26,000. Leonteq Securities AG acquired a new position in shares of BeOne Medicines during the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines in the 2nd quarter worth approximately $35,000. Finally, CWM LLC grew its holdings in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Guggenheim raised its price target to $410 from $400 and kept a Buy rating, implying ~27.6% upside versus the current price — a bullish signal that likely supported the stock earlier in the session. Article Title
• Positive Sentiment: Barclays raised its price target to $405 from $394 and maintained an Overweight rating, suggesting ~26.0% upside and adding further analyst optimism intraday. Article Title
• Neutral Sentiment: Earnings call presentation and slides were posted, providing management detail on Q4 results and outlook for investors to review before making longer-term positioning decisions. Earnings Call Presentation
• Neutral Sentiment: Analyst write-ups (Zacks, Yahoo) provide metric-level context on the quarter and broader valuation questions after multi-year gains — useful for framing risk/reward but not immediate catalysts. Zacks Analysis
• Neutral Sentiment: Reported short-interest figures in the feed appear inconsistent/garbled (zero shares, NaN changes) and are unlikely to be a meaningful immediate driver until clarified by reliable filings.
• Negative Sentiment: Q4 EPS missed estimates: reported $0.58 vs. $1.60 consensus (miss of $1.02), although revenue beat at $1.50B vs. $1.45B — an earnings shortfall that pressured sentiment. MarketBeat EPS/Revenue
• Negative Sentiment: FY2026 revenue guidance was lowered to about $6.2–$6.4B versus Street ~ $6.5B; the softer guide, coupled with mixed quarter, prompted downward reaction in some coverage. Investing.com
• Negative Sentiment: News coverage framed the quarter as an earnings miss despite profitability and noted the stock’s decline on the results and guidance — reinforcing negative near-term sentiment. Yicai Global

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.